Global Anti-Epileptic Drug Market to Reach $9.5 Billion by 2022

April 04, 2018

WELLESLEY, Mass., April 04, 2018–An aging global population, growth from developing nations and an increasing frequency of head injuries due to road accidents are helping boost growth in the global market for anti-epileptic drugs, according to a report by BCC Research.

The global market for the industry was valued at $8.4 billion in 2017, and is forecasted to grow at a compound annual growth rate (CAGR) of 2.7% through 2022, when it will be worth an estimated $9.5 billion, according to the report Anti-Epileptic Drugs Market: Global Markets to 2022.

Major players in the market include Pfizer Inc., UCB Biosciences Inc., GlaxoSmithKline PLC, Sanofi, Eisai Inc., Otsuka Pharmaceutical LTD., H. Lundbeck, Sumitomo Dainippon Pharma Co. and Shire PLC.

Research Highlights

• North America is the largest market for anti-epileptic drugs manufacturing, accounting for 33.9% of the global market. It is followed by the Asia-Pacific region and Western Europe. Eastern Europe is expected to witness the fastest market growth, with CAGR of 5.4% through 2022.
• By country, the United States is the world’s largest anti-epileptic drugs market, in terms of value. Russia and India are forecasted to have the fastest growth, with CAGRs of 4.6% and 4.0%, respectively.
• Second-generation anti-epileptic drugs accounted for the largest share of the market in 2017 at 44.3%. The highest growth is projected to come from third-generation antiepileptic drugs, which are forecasted to grow at a CAGR of 3.1%

“The rapid growth of elderly populations in many developed countries and economies around the world is driving the demand for anti-epileptic drugs,” said Robert G. Hunter, BCC Research senior editor, healthcare. “The aging demographic is growing at a rapid pace in Japan, and European countries such as Italy, Greece and Germany. For instance, in Japan, the number of elderly people aged 65 or above accounts for about 26.7% of the total population.”

Patent Expiration Seen as a Major Restraint on the Market

The biggest restraint on the market is likely the looming expiration of drug patents. Pharmaceutical companies invest huge sums of money in the drug development process, but when patents expire, generic versions of the drug flood the market and drive prices down. The prices of these generics are low in comparison to the original brand of the drug. For instance, the patent for Sabril, an anti-epileptic drug developed by Lundbeck LLC, expired in 2017, after which a generic version of the drug is being manufactured by Par Pharmaceuticals – negatively impacting growth of the overall market in value.

Editors/reporters requesting analyst interviews should contact steven.cumming@bccresearch.com.

Anti-Epileptic Drugs: Global Markets to 2022( PHM197A )
Publish Date: Mar 2018    

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.